Keywords: rhatiii, dropped, primary, indication, genzyme, transgenics, corp

rhATIII dropped for primary indication

Article | 08 February 2001

Print This

Genzyme Transgenics Corp has said that it does not expect to reacquirerights to recombinant human antithrombin III from its ATIII ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in